Related references
Note: Only part of the references are listed.A multi-targeted approach to treating bone metastases
Daniel F. Camacho et al.
CANCER AND METASTASIS REVIEWS (2014)
Bone-targeting agents in prostate cancer
Daniel L. Suzman et al.
CANCER AND METASTASIS REVIEWS (2014)
Integrating new discoveries into the vicious cycle paradigm of prostate to bone metastases
Leah M. Cook et al.
CANCER AND METASTASIS REVIEWS (2014)
Recent advances in bone-targeted therapies of metastatic prostate cancer
Xiyun Deng et al.
CANCER TREATMENT REVIEWS (2014)
Decorin Induces Mitophagy in Breast Carcinoma Cells via Peroxisome Proliferator- activated Receptor γ Coactivator-1α ( PGC-1 α) and Mitostatin*
Thomas Neill et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Ad5/48 Hexon Oncolytic Virus Expressing sTGFβRIIFc Produces Reduced Hepatic and Systemic Toxicities and Inhibits Prostate Cancer Bone Metastases
Weidong Xu et al.
MOLECULAR THERAPY (2014)
Managing bone metastases and reducing skeletal related events in prostate cancer
Benjamin A. Gartrell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers
I-K Choi et al.
CANCER GENE THERAPY (2013)
Targeting MET and Vascular Endothelial Growth Factor Receptor Signaling in Castration-Resistant Prostate Cancer
Richard J. Lee et al.
CANCER JOURNAL (2013)
More than matrix: The multifaceted role of decorin in cancer
David Denis Sofeu Feugaing et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2013)
Decorin A Guardian from the Matrix
Thomas Neill et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host
Z. Zhang et al.
CANCER GENE THERAPY (2012)
Systemic Delivery of Oncolytic Adenoviruses Targeting Transforming Growth Factor-β Inhibits Established Bone Metastasis in a Prostate Cancer Mouse Model
Zebin Hu et al.
HUMAN GENE THERAPY (2012)
Decorin Antagonizes the Angiogenic Network CONCURRENT INHIBITION OF MET, HYPOXIA INDUCIBLE FACTOR 1α, VASCULAR ENDOTHELIAL GROWTH FACTOR A, AND INDUCTION OF THROMBOSPONDIN-1 AND TIMP3
Thomas Neill et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth
Xin Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Wnt/β-catenin signalling in prostate cancer
Robert M. Kypta et al.
NATURE REVIEWS UROLOGY (2012)
Proteoglycans in prostate cancer
Iris J. Edwards
NATURE REVIEWS UROLOGY (2012)
Stromal Expression of Decorin, Semaphorin6D, SPARC, Sprouty1 and Tsukushi in Developing Prostate and Decreased Levels of Decorin in Prostate Cancer
Alexander Henke et al.
PLOS ONE (2012)
Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors
Allan Lipton et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2012)
MET and VEGF: synergistic targets in castration-resistant prostate cancer
Dana T. Aftab et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2011)
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials
Andreas Varkaris et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Systemic Delivery of a Novel Liver-Detargeted Oncolytic Adenovirus Causes Reduced Liver Toxicity but Maintains the Antitumor Response in a Breast Cancer Bone Metastasis Model
Zhenwei Zhang et al.
HUMAN GENE THERAPY (2011)
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi et al.
LANCET (2011)
Oncolytic Adenovirus Expressing Soluble TGFβ Receptor II-Fc-mediated Inhibition of Established Bone Metastases: A Safe and Effective Systemic Therapeutic Approach for Breast Cancer
Zebin Hu et al.
MOLECULAR THERAPY (2011)
A Perspective on Cancer Cell Metastasis
Christine L. Chaffer et al.
SCIENCE (2011)
A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFβ signaling for breast cancer therapy
Z. Hu et al.
CANCER GENE THERAPY (2010)
Effect of decorin on overcoming the extracellular matrix barrier for oncolytic virotherapy
I-K Choi et al.
GENE THERAPY (2010)
Clinical Adenoviral Gene Therapy for Prostate Cancer
Ellen Schenk et al.
HUMAN GENE THERAPY (2010)
Systemic Delivery of an Oncolytic Adenovirus Expressing Soluble Transforming Growth Factor-β Receptor II-Fc Fusion Protein Can Inhibit Breast Cancer Bone Metastasis in a Mouse Model
Zebin Hu et al.
HUMAN GENE THERAPY (2010)
Decorin Antagonizes Met Receptor Activity and Down-regulates β-Catenin and Myc Levels
Simone Buraschi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Current Issues and Future Directions of Oncolytic Adenoviruses
Masato Yamamoto et al.
MOLECULAR THERAPY (2010)
Examining the Metastatic Niche: Targeting the Microenvironment
Theresa Guise
SEMINARS IN ONCOLOGY (2010)
Loss of PINK1 Function Promotes Mitophagy through Effects on Oxidative Stress and Mitochondrial Fission
Ruben K. Dagda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Decorin is a novel antagonistic ligand of the Met receptor
Silvia Goldoni et al.
JOURNAL OF CELL BIOLOGY (2009)
An antimetastatic role for decorin in breast cancer
Silvia Goldoni et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Role of decorin in the antimyeloma effects of osteoblasts
Xin Li et al.
BLOOD (2008)
A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis
Seiichi Munesue et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-β receptor II and human immunoglobulin Fc for breast cancer therapy
Prem Seth et al.
HUMAN GENE THERAPY (2006)
Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis
Yiping Zeng et al.
CANCER RESEARCH (2006)
Bone turnover mediates preferential localization of prostate cancer in the skeleton
A Schneider et al.
ENDOCRINOLOGY (2005)
Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin
CC Reed et al.
ONCOGENE (2002)
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
RE Coleman
CANCER TREATMENT REVIEWS (2001)
A high-throughput x-ray microtomography system at the Advanced Photon Source
YX Wang et al.
REVIEW OF SCIENTIFIC INSTRUMENTS (2001)
Share Paper
